

TABLE OF CONTENTS

0. Executive Summary	16
1. Basic Aspects of Pain	18
Introduction	18
Historical aspects of pain	18
Pain definitions	20
A glossary of terms relevant to pain	21
Pain classification and description	21
Neuropathic pain.....	22
Cancer pain.....	24
<i>Bone pain in cancer.....</i>	<i>26</i>
Complex regional pain syndrome	26
Mechanisms of pain	27
Pain pathways	27
<i>Role of nociceptors in pain transmission.....</i>	<i>28</i>
Gate control and neuromatrix theories of pain	29
Pain mediators	30
Modulation of pain by pictures associated with social contacts	30
Modulation of pain by emotions	30
Role of the sympathetic nervous system in pain.....	31
Visceral pain.....	31
<i>Pathomechanism of visceral pain</i>	<i>31</i>
Pathomechanism of neuropathic pain	32
<i>Role of intact nerve fibers in neuropathic pain</i>	<i>32</i>
<i>Chemokines as mediators of neuropathic pain</i>	<i>32</i>
<i>Chemotherapy-induced neuropathic pain</i>	<i>33</i>
<i>CNS innate immunity and neuropathic pain</i>	<i>33</i>
<i>Cytokines as mediators of neuropathic pain.....</i>	<i>33</i>
<i>Free radicals in generation of neuropathic pain</i>	<i>33</i>
<i>Genetic basis of neuropathic pain.....</i>	<i>34</i>
<i>Gene expression changes in neuropathic pain.....</i>	<i>34</i>
<i>Glial activation and neuropathic pain</i>	<i>35</i>
<i>Immune cell-derived opioids and neuropathic pain</i>	<i>35</i>
<i>Spinal leptin and neuropathic pain</i>	<i>35</i>
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity</i>	<i>36</i>
Pathomechanism of migraine.....	36
Role of the immune system in pain	37
Pain and itch	37
<i>Pathomechanism of itch.....</i>	<i>37</i>
<i>Clinical aspects of itch</i>	<i>38</i>
Molecular pathophysiology of pain.....	38
Role of ion channels in pain.....	38
<i>Role of sodium channels in pain.....</i>	<i>39</i>
<i>Role of potassium ion channels.....</i>	<i>40</i>
<i>Role of calcium channels in pain</i>	<i>40</i>
<i>Acid-sensing ion channels.....</i>	<i>41</i>
<i>P2X3 ion channels.....</i>	<i>41</i>
<i>Role of TRP ion channels in pain.....</i>	<i>42</i>
Genetic basis of pain	42
<i>Study of genes in pain.....</i>	<i>43</i>
Pain in the brain	44
<i>Neuropathic pain-induced morphological changes in the brain</i>	<i>44</i>
Change from acute to chronic pain	44
<i>Descending facilitatory modulation of pain</i>	<i>45</i>
<i>Development of chronic pain following severe accidental injury.....</i>	<i>45</i>
<i>Pain and transcriptional repressor DREAM</i>	<i>46</i>
<i>Role of neuronal plasticity in pain.....</i>	<i>46</i>
Neurochemistry of pain.....	46
<i>Molecular elements of pain in the peripheral nervous system.....</i>	<i>46</i>
<i>Molecular elements of pain in the central nervous system</i>	<i>47</i>
<i>Opioid receptors</i>	<i>48</i>
<i>Role of AMPA receptors in chronic pain</i>	<i>48</i>
<i>Kinins.....</i>	<i>48</i>
<i>Serotonin.....</i>	<i>49</i>
<i>Substance P</i>	<i>49</i>
<i>Excitatory amino acids.....</i>	<i>49</i>
<i>Role of nitric oxide in pain.....</i>	<i>49</i>
<i>Prostaglandins</i>	<i>50</i>

<i>Endocannabinoids</i>	51
<i>Protein kinase C</i>	51
<i>Adenosine and adenosine receptors</i>	52
<i>Vitamin D and pain</i>	52
<i>Vanilloid receptor</i>	52
<i>TRP_{A1} and TRP_{V1} receptors</i>	52
<i>Endothelin-B receptors</i>	54
<i>Nerve growth factor and pain</i>	54
<i>Adrenomedullin as a pain-related peptide</i>	54
Biomarkers of pain	54
<i>Biomarkers of visceral pain</i>	55
2. Assessment of Pain and Analgesics	56
Introduction	56
Animal models of pain	56
An overview	56
Selection of animal species as models for pain.....	56
Types of noxious stimuli	57
Animal models of neuropathic pain.....	57
Animal models of arthritis	57
Animal models of peripheral neuropathy	58
Limitations of current pain models	58
Biogenic animal model of chronic pain	59
Ethical issues concerning animal pain models	59
Medical evaluation of pain	60
Chronic pain as a manifestation of various diseases	60
Assessment of pain patients	60
Medical examination.....	60
Measurement of pain.....	61
Quantitative sensory testing.....	62
Pain measurement tools for neonates and children.....	63
Quantitative sensory testing.....	63
Psychological assessment of pain	64
Brain imaging in pain	64
<i>PET for study of pain</i>	64
<i>PET correlated with fMRI and evoked potentials</i>	65
Patient outcomes and quality of life during treatment for chronic pain	65
Collection and analysis of data on pain patients	66
Evaluation of analgesics in humans	66
Early phase clinical trials of analgesics in humans	66
Design of clinical trials for pain	67
Assessment of neuropathic pain.....	68
Transdermal electrical stimulation for study of chronic pain.....	68
Placebo effect in pain	69
Role of electronic pain recording in determination of the placebo effect.....	69
Outcome measures for chronic pain trials.....	70
Pain, pain therapies and cognitive function.....	70
3. Pharmacotherapy of Pain.....	72
Introduction	72
Mechanism of action of currently used pain medications	72
Non-steroidal antiinflammatory drugs	73
COX-2 inhibitors	73
<i>Celecoxib</i>	74
<i>Metamizole</i>	75
<i>Nimesulide</i>	75
<i>Rofecoxib</i>	75
<i>Valdecoxib</i>	76
<i>Lumiracoxib</i>	76
<i>Side effects of COX inhibitors</i>	76
<i>Innovative COX-2 inhibitors in development</i>	78
Acetaminophen.....	79
Antioxidants as analgesics.....	79
Opiates and opioids	79
Innovations in opioid therapy	80
<i>Oral transmucosal fentanyl</i>	81
<i>Use of opioids for chronic non-cancer pain</i>	81
Opioid receptor modulation for visceral pain	81
Opiorphin.....	82
N-methyl-D-aspartate receptor antagonists	82
Ketamine	82

CNS 5161	82
Triptans for treatment of non-migrainous pain	83
Capsaicin	83
NGX-4010	83
Local anesthetics	84
Topical application	84
Nerve blocks	84
<i>Injection of local anesthetics for analgesia</i>	<i>84</i>
<i>Ultrasound-guided nerve blocks</i>	<i>85</i>
Topical salicylates for the treatment of pain	85
Topical rubefaciants for acute and chronic pain in adults	85
Adjunctive analgesics	85
Antidepressants	86
<i>Mechanism of analgesic action of antidepressants</i>	<i>87</i>
Antiepileptic drugs	87
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	<i>88</i>
Carbamazepine	89
Gabapentin	89
Lamotrigine	89
Phenytoin	90
Pregabalin	90
Topiramate	91
Valproic acid	91
Other antiepileptic drugs	91
Clonidine	92
Baclofen	92
Corticosteroids	92
Calcitonin	93
Bisphosphonates	93
Botulinum toxins	94
Analgesic effect of botulinum toxin A	94
Engineered botulinum toxin	94
Analgesics from traditional medical systems	95
Herbs and other plants	95
Analgesics derived from cobra toxin	96
Adverse effects of analgesics	96
Gastrointestinal adverse effects of NSAIDs	96
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs</i>	<i>96</i>
Cardiovascular adverse effects of COX-2 inhibitors	97
Adverse effects of opioids	97
<i>Risk of addiction and development of tolerance</i>	<i>97</i>
<i>Companies developing products to deter abuse of opioids</i>	<i>98</i>
<i>Remoxy versus Oxycontin</i>	<i>98</i>
<i>Hyperalgesia associated with opioids</i>	<i>98</i>
<i>Respiratory depression</i>	<i>99</i>
<i>Opioid-associated constipation</i>	<i>99</i>
<i>Narcotic bowel syndrome</i>	<i>99</i>
Approaches to reduce adverse effects of opioids	100
<i>PEGylated naloxol</i>	<i>100</i>
<i>Innovative approaches to modify opioid pharmacology</i>	<i>100</i>
Adverse effects of miscellaneous non-narcotic analgesics	100
<i>Adverse effects of immunosuppressants used for relief of pain</i>	<i>101</i>
<i>Adverse effects of acetaminophen</i>	<i>101</i>
4. Management of Pain	102
Introduction	102
Sites for pain management	102
Self-medication at home	102
Physicians' offices	102
Major hospitals	102
Pain centers	103
Non-pharmacological approaches to pain	103
Alternative medicine	103
<i>Acupuncture</i>	<i>104</i>
<i>Aromatherapy</i>	<i>104</i>
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	<i>105</i>
Behavioral therapy	105
<i>Cognition and pain</i>	<i>105</i>
<i>Control over brain activation and pain by using functional MRI</i>	<i>105</i>
<i>Virtual reality therapy</i>	<i>106</i>
Local application of heat	106

Transcutaneous nerve stimulation	106
Transcranial magnetic stimulation	107
Neurosurgery for pain relief.....	107
<i>Ablative procedures on the nervous system.....</i>	<i>107</i>
<i>Procedures on peripheral, spinal and cranial nerves.....</i>	<i>107</i>
<i>Vagal nerve stimulation for control of pain</i>	<i>108</i>
<i>Neuromodulation</i>	<i>108</i>
<i>Spinal cord stimulation</i>	<i>109</i>
<i>Brain stimulation.....</i>	<i>109</i>
<i>Implantation of drug delivery devices</i>	<i>109</i>
Management of special types of pain	110
Acute pain	110
<i>Management of acute renal colic: NSAIDs vs. opioids.....</i>	<i>110</i>
<i>Combination of opioids and NSAIDs for acute pain</i>	<i>110</i>
<i>Reasons for inadequate management of acute pain</i>	<i>110</i>
Perioperative pain management.....	111
<i>Devices for delivery of analgesics in the postoperative period</i>	<i>111</i>
<i>Drug combination for perioperative pain</i>	<i>112</i>
<i>Gabapentin for reduction of postoperative pain.....</i>	<i>113</i>
<i>Ketamine for perioperative pain.....</i>	<i>113</i>
<i>Opioids for perioperative pain.....</i>	<i>113</i>
<i>Perioperative pain in neurosurgery.....</i>	<i>114</i>
<i>Prolonged duration local anesthesia.....</i>	<i>114</i>
Pain in the intensive care unit.....	114
Pain associated with sports and exercise.....	115
Pain associated with trauma.....	115
Chronic abdominal pain	116
Functional somatic syndromes	116
Fibromyalgia syndrome.....	117
<i>Pathomechanism of FMS.....</i>	<i>117</i>
<i>Management of FMS.....</i>	<i>117</i>
<i>New developments in pharmacotherapy of FMS</i>	<i>118</i>
Erythromelalgia	119
Irritable bowel syndrome	119
<i>Opioids for IBS</i>	<i>120</i>
<i>Tricyclic antidepressants for IBS</i>	<i>120</i>
<i>Serotonin-modulating drugs for IBS</i>	<i>121</i>
Musculoskeletal pain	121
Myofascial pain syndrome	121
Osteoarthritis	122
<i>Pathomechanism of osteoarthritis</i>	<i>122</i>
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	<i>123</i>
<i>Management of osteoarthritis</i>	<i>123</i>
Rheumatoid arthritis.....	124
<i>Management of pain in rheumatoid arthritis</i>	<i>125</i>
<i>Disease modifying therapies in rheumatoid arthritis</i>	<i>125</i>
<i>Resurgence of interest in gold-based treatments for RA.....</i>	<i>126</i>
Backache	126
<i>Use of analgesics for management of back pain</i>	<i>127</i>
<i>Miscellaneous medical therapies for backache and sciatica</i>	<i>128</i>
Neck pain.....	128
Chronic pelvic pain.....	129
<i>Prostatitis</i>	<i>129</i>
Cancer pain.....	129
<i>Opioid treatment of cancer pain.....</i>	<i>130</i>
<i>Breakthrough and opioid-insensitive pains</i>	<i>131</i>
<i>Morphine-induced enhancement of cancer growth and its prevention.....</i>	<i>131</i>
<i>Methods of delivery of opioids for cancer pain.....</i>	<i>132</i>
<i>Implantation of drug delivery devices</i>	<i>132</i>
<i>Management of bone pain in cancer</i>	<i>133</i>
<i>Use of non-opioid analgesics for cancer pain.....</i>	<i>133</i>
<i>Adjuvant drugs for cancer pain</i>	<i>133</i>
<i>Radiation therapy</i>	<i>134</i>
<i>Alternative non-pharmacological methods.....</i>	<i>134</i>
<i>Anesthetic techniques.....</i>	<i>134</i>
<i>Surgical methods of cancer pain relief</i>	<i>134</i>
<i>Conclusions regarding management of cancer pain</i>	<i>135</i>
Chronic non-malignant pain	135
Headache.....	135
<i>Migraine</i>	<i>136</i>
<i>Management of acute migraine.....</i>	<i>136</i>

<i>Neurostimulation for migraine</i>	140
<i>Transcranial magnetic stimulation for migraine</i>	141
<i>Migraine prophylaxis</i>	141
<i>Cluster headache</i>	141
<i>Tension headache</i>	142
<i>Chronic daily headache</i>	142
Trigeminal neuralgia	143
Dental pain	143
Neuropathic pain	144
<i>Pathogenesis of neuropathic pain</i>	144
<i>Chronobiology of neuropathic pain as guide to therapy</i>	145
<i>Management of neuropathic pain based on mechanism</i>	145
<i>Guidelines for the management of neuropathic pain</i>	146
<i>Pharmacotherapy of neuropathic pain</i>	146
<i>Evidence-based management of neuropathic pain</i>	148
Management of central neuropathic pain	148
<i>Neurosurgical approaches to central neuropathic pain</i>	149
<i>Management of neuropathic pain in syringomyelia</i>	149
<i>Neuropathic pain associated with spinal cord injury</i>	150
Peripheral neuropathic pain	150
<i>Management of postsurgical peripheral neuropathic pain</i>	150
<i>Management of chemotherapy-induced pain</i>	151
<i>Morton's neuroma</i>	151
<i>Management of peripheral diabetic neuropathy</i>	152
<i>Postherpetic neuralgia</i>	153
<i>Complex regional pain syndrome</i>	155
<i>An algorithm for the management of peripheral neuropathic pain</i>	156
Phantom limb pain	157
<i>Pathomechanism of phantom limb pain</i>	157
<i>Management of phantom limb pain</i>	158
Pain and depression	160
<i>Neurochemical link between pain and depression</i>	160
<i>Management of chronic pain and depression</i>	161
Miscellaneous painful conditions	162
<i>Burning mouth syndrome</i>	162
<i>Chronic unstable angina</i>	162
<i>Mastalgia</i>	162
<i>Ophthalmic pain</i>	163
<i>Pain in Parkinson's disease</i>	163
Management of itching	163
<i>Topical applications for itching</i>	164
<i>Systemic therapies for itching</i>	165
<i>Non-pharmacological therapies for itch</i>	166
Management of pain in special population groups	166
Racial and ethnic differences in pain management	166
Pain in neonates	166
Management of pain in children	167
Management of pain in the elderly	167
Management of pain in women	168
<i>Reasons for increased pain perception in women</i>	169
<i>Chronic pelvic pain in women</i>	169
<i>Gender differences in response to analgesics</i>	169
<i>Considerations for pain management in women</i>	170
Management of pain in neurologically handicapped persons	170
Management of pain in the cognitively impaired elderly people	170
Management of pain in brain-damaged minimally conscious patients	171
Management of pain in the terminally ill	171
Deficiencies in the management of pain	172
Negative physician attitudes in pain management	172
Suggestions for improvement of pain management by healthcare providers	173
Pain as the fifth vital sign	174
Multidisciplinary approaches to pain management	174
5. Drug Delivery for Pain	176
Introduction	176
Intra-articular injection for relief of joint pain	177
Controlled release drug delivery for pain	177
Accelerating the effect of subcutaneous morphine	177
Controlled drug delivery at site of pain	177
Oral extended release opioids	178
<i>Extended release oral morphine</i>	178

<i>Controlled release oxycodone</i>	179
<i>Extended release oxymorphone</i>	179
<i>Oral extended release tramadol</i>	179
Extended release gabapentin	180
Use of nanotechnology for drug delivery for pain	180
Non-injection methods of delivery of analgesics	180
Topical applications for pain	181
<i>Topical local anesthetics</i>	181
<i>Topical NSAIDs</i>	181
<i>Topical and transdermal diclofenac</i>	182
<i>Topical application for postoperative pain</i>	183
Needle-free drug delivery for pain	183
<i>Glide SDI® solid dose injector</i>	183
<i>SUMAVEL™ DosePro™ needle-less injection</i>	183
Transdermal drug delivery for pain	183
<i>Relief of pain associated with minor medical procedures</i>	184
<i>Transdermal fentanyl</i>	184
<i>Transdermal ketoprofen</i>	185
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	186
<i>Transdermal buprenorphine</i>	186
<i>Transdermal trans-capsaicin</i>	186
<i>Powder Injection Systems</i>	187
Intranasal delivery of analgesics	187
<i>Intranasal morphine</i>	188
<i>Intranasal morphine derivatives</i>	188
<i>Intranasal fentanyl</i>	189
<i>Intranasal buprenorphine</i>	189
<i>Intranasal ketamine</i>	189
<i>Intranasal ketorolac</i>	190
<i>Nasal formulations for migraine</i>	190
Oral spray formulations for migraine	190
Delivery of analgesics by inhalation	191
Buccal transmucosal and sublingual delivery of analgesics	192
<i>Application for cancer pain</i>	192
<i>Application for non-cancer pain</i>	192
Pumps for drug delivery in pain	193
<i>Patient controlled analgesia</i>	193
<i>Postoperative pain pumps</i>	193
<i>Chronogestic (sufentanil) Pain Therapy System</i>	194
<i>Spinal pumps for delivery of analgesics</i>	195
Spinal delivery of analgesics	195
Epidural administration of analgesics	196
<i>Epidural dexamethasone</i>	196
<i>Epidural etanercept</i>	196
<i>Epidural morphine</i>	197
Intrathecal administration of analgesics	197
<i>Intrathecal ziconotide</i>	197
<i>Intrathecal CGX1160</i>	198
<i>Intrathecal neostigmine</i>	198
<i>Intrathecal prostaglandin antagonists</i>	198
<i>Intrathecal non-NMDA antagonists</i>	199
<i>Intrathecal fadolmidine</i>	199
<i>Intrathecal resiniferatoxin</i>	199
<i>Concluding remarks on intrathecal delivery of analgesic agents</i>	199
Intracerebroventricular morphine for pain	200
Development of drug delivery systems for pain therapy	200
Delivery of analgesics to the CNS across the blood brain barrier	200
Drug delivery systems in clinical trials	201
6. Drug Development for Pain	204
Introduction	204
Drugs in development for pain	204
Current research goals	205
The ideal analgesic	205
Pain R & D goals in the pharmaceutical industry	205
Drug targets in the spinal cord	206
Drug targets in the brain	206
Molecular targets for analgesic drugs	206
Activation of P2X7 receptors	206
Adenosine receptor agonists	207
Alfa2-adrenergic receptor agonists	207

Bradykinin antagonists	207
Cannabinoids.....	208
<i>Cannabinoid receptor agonists</i>	208
<i>Cannabidiol</i>	210
<i>Cannabinor</i>	211
<i>Nabilone</i>	211
Capsaicin and VR1 receptor-based analgesics.....	212
<i>Vanilloid (capsaicin) receptor antagonists</i>	212
<i>VR1 receptor agonists</i>	212
CCR2 receptor blockade.....	213
Cholecystokinin antagonists	213
Cholinergic receptor agonists.....	213
Conotoxins as analgesics	214
Corticotropin-releasing factor	215
FAAH inhibitors.....	215
<i>PF-3845</i>	216
<i>URB597</i>	216
Free radical scavengers as analgesics.....	216
<i>Superoxide dismutase mimetics</i>	217
GABA analogues	217
<i>Subtype-selective GABAergic drugs</i>	217
Glial cell line-derived neurotrophic factor	218
Glutamate receptor antagonists	218
<i>NMDA receptor modulation for neuropathic pain</i>	218
<i>Alternatives to direct blocking of NMDA receptors</i>	218
<i>Glycine antagonists</i>	219
<i>Metabotropic glutamate receptors</i>	219
Histgranin-like compounds for the management of pain	219
Ion channels as targets for analgesic drugs.....	220
<i>Acid-sensing ion channels as drug target</i>	220
<i>Calcium channel blockers</i>	221
<i>P2X ion channel receptor antagonists</i>	221
<i>Sodium channel modulation</i>	222
<i>Mas-related GPCR agonists</i>	222
Microsomal prostaglandin E synthase inhibitors	223
NAALADase inhibitors	224
Nerve growth factor antagonists	224
Newer COX inhibitors	224
<i>COX-3 inhibitors</i>	224
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	225
Neuropeptide receptor antagonists for improving the efficacy of opioids.....	225
Nicotinic acetylcholine receptors	225
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	226
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	226
Nitric oxide-based analgesics.....	227
<i>Nitric oxide-releasing NSAIDs</i>	227
<i>Pharmacology of NO-SAIDs</i>	228
<i>COX-inhibiting nitric oxide donors</i>	228
<i>NO-donating structures to extend life cycle of existing analgesics</i>	228
<i>Nitric oxide mimetics</i>	229
<i>Neuronal nitric oxide synthase inhibitors</i>	229
Norepinephrine transporter inhibition	229
Opioid peptide receptors ligands	230
<i>Buprenorphine</i>	231
<i>Nociceptin</i>	231
<i>Tapentadol</i>	231
Opioid analgesics acting outside the CNS	232
<i>Opioid analgesics acting at peripheral receptors</i>	232
<i>Peripherally acting mu-opioid receptor agonists</i>	232
<i>Targeting of opioid peptide-containing immune cells</i>	233
<i>Advantages of peripherally selective opioid drugs</i>	233
Resolvins	233
Somatostatin analogs	234
Substance P and neurokinin receptor antagonists.....	234
Substance P-Saporin	234
Targeting prostanoid synthesis	235
Tetrodotoxin based analgesics	236
TRPV1 antagonists	236
<i>TRPV1 antagonists in clinical trials</i>	237
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	237
Tumor necrosis factor- α antagonists.....	238

Cell and gene therapies for pain	238
Cell therapy	238
<i>Implantation of chromaffin cells.....</i>	239
<i>Role of stem cells in management of pain</i>	239
<i>Implantation of astrocytes secreting enkephalin.....</i>	240
<i>Cells for delivery of antinociceptive molecules</i>	240
<i>Implantation of genetically engineered cells</i>	240
<i>Cell therapy for low back pain.....</i>	241
<i>Cell therapy for knee pain due to degenerative disorders</i>	241
<i>Cell therapy for peripheral neuropathy.....</i>	242
<i>Concluding remarks on cell therapy for pain</i>	242
Gene therapy	242
<i>Rationale of gene therapy for pain</i>	243
<i>Vectors for gene therapy of pain</i>	243
<i>Methods of gene delivery for pain</i>	244
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	244
<i>Gene delivery by intrathecal route</i>	245
<i>Gene transfer to the dorsal nerve roots</i>	245
<i>Gene therapy of peripheral neuropathy.....</i>	246
<i>Gene transfer by injections into the brain substance.....</i>	247
<i>Zinc finger DNA-binding protein therapeutic for chronic pain</i>	247
<i>Gene therapy for producing enkephalin to block pain signals</i>	247
<i>Targeting nuclear factor-κB.....</i>	248
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	248
<i>Antisense therapy for pain</i>	249
<i>RNAi-based approaches for pain therapy.....</i>	249
<i>Potential applications of gene therapy for management of pain.....</i>	250
<i>Concluding remarks about gene therapy for pain</i>	250
Preclinical development of pain drugs	251
NGF-blocking antibody.....	252
Prostatic acid phosphatase as a novel analgesic.....	252
Preclinical development of drugs for neuropathic pain.....	253
<i>5-HT receptor agonists</i>	254
<i>A-803467.....</i>	254
<i>AM1241</i>	254
<i>Artemin/Neuroblastin</i>	255
<i>Capsazepine.....</i>	255
<i>Central nACh receptor agonists.....</i>	255
<i>CGP 35024.....</i>	256
<i>Drugs that suppress glial activation</i>	256
<i>Erythropoietin.....</i>	257
Gene therapy for neuropathic pain	257
<i>NCX 8001</i>	257
<i>NR2B subtype NMDA receptor ligands.....</i>	258
<i>NW-1029.....</i>	258
<i>R116301.....</i>	258
<i>Targeting tumor necrosis factor</i>	259
Future targets for osteoarthritic pain	259
Pain drugs in clinical trials.....	259
Clinical trials of miscellaneous drugs for pain.....	259
<i>Alvimopan.....</i>	261
<i>Asimadoline</i>	262
<i>EN3202</i>	262
<i>Oxytrex</i>	262
Drugs in clinical trials for postsurgical pain	263
<i>Bicifadine.....</i>	264
<i>DepoMorphine</i>	264
<i>TC-2696</i>	265
Cox-2 inhibitors in clinical trials	265
Clinical trials of disease modifying therapies for rheumatoid arthritis	265
Drugs in clinical development for neuropathic pain.....	267
<i>Adenosine A1 agonists for neuropathic pain</i>	269
<i>Botulinum toxin type A</i>	269
<i>CPL7075.....</i>	270
<i>D-amino acid oxidase inhibitors</i>	270
<i>Glyx-13</i>	270
<i>IP-751</i>	271
<i>Lacosamide.....</i>	271
<i>Oxcarbazepine.....</i>	272
<i>Perampanel.....</i>	272
<i>Ralfinamide.....</i>	272

<i>Retigabine</i>	272
<i>SB-509</i>	273
<i>SCP-1</i>	273
<i>TC-6499</i>	273
<i>Tebanicline</i>	273
<i>Tezampanel</i>	274
<i>Thalidomide</i>	274
<i>TRO19622</i>	274
<i>V3381 (indantadol)</i>	275
<i>XP-13512</i>	275
<i>Zonisamide</i>	275
Drug discovery and development for migraine.....	276
<i>Drugs in clinical development for migraine</i>	276
Drug development for visceral pain.....	279
7. Legal and regulatory issues of pain management.....	280
Pain relief as a legal right.....	280
Pain relief and the WHO.....	280
Regulatory issues.....	280
Opioids and cannabinoids.....	280
DEA and use of opioids for pain relief in terminal care.....	280
FDA and COX-2 inhibitors.....	281
Legal issues of COX-2 inhibitors.....	282
Regulatory issues of opioid safety.....	282
Opioid misuse and regulatory agencies.....	282
FDA measures for safety of opioid use.....	282
Misuse of fentanyl.....	283
8. Pain Markets.....	284
Introduction.....	284
Epidemiological basis of pain markets.....	284
Cancer.....	285
Neuropathic pain.....	285
Trigeminal neuralgia.....	285
Arthritis.....	285
Backache.....	285
Migraine.....	286
Multiple sclerosis.....	286
Irritable bowel syndrome.....	286
Chronic pelvic pain.....	286
Chronic pain due to traumatic brain injury.....	286
Postsurgical pain.....	287
Economics of pain.....	287
Pain as a driver of healthcare costs.....	287
Disability and financial loss through pain.....	288
Pain markets based on painful conditions.....	288
The cancer pain market.....	288
The arthritis pain market.....	289
Postsurgical pain market.....	289
The backache market.....	289
The headache market.....	290
Neuropathic pain market.....	290
Fibromyalgia market.....	291
Pain markets based on drugs.....	291
Opioids.....	291
Nonsteroidal antiinflammatory drugs.....	291
Transdermal pain therapeutics.....	292
Anesthesia.....	292
Antiepileptic drugs as analgesics.....	292
Other drugs.....	293
Hospital vs retail share of pain market.....	293
<i>Hospital versus retail opioid market</i>	293
Devices for pain.....	293
Pain markets according to geographical areas.....	293
Cost effectiveness of various approaches.....	294
Unfulfilled R&D needs in pain therapy.....	294
Under treatment of pain.....	294
Unfulfilled needs in drug development for chronic pain.....	295
Strategies for developing pain markets.....	295
Finding alternatives to intrathecal administration for chronic pain.....	296
Development of other applications of analgesic drugs.....	296

Partnership of patients, pharmacists and companies.....	297
Factors that may influence future pain markets	297
Drivers of pain markets	297
Public surveys as indicators of impact of pain on people.....	297
Effect of regulatory reviews on markets for pain products	298
Novel versus older therapies for pain.....	298
9. Future of Pain Therapeutics.....	300
Introduction	300
Advances in the understanding of pain	300
Pathogenesis of chronic pain	300
Role of glia in neuropathic pain.....	300
Molecular and neurobiological techniques.....	301
Improved understanding of cancer pain	302
Advances in drug discovery and development for pain	302
Novel targets for drug discovery for pain	302
<i>PTH2 receptor</i>	302
<i>Modulators of endogenous cannabinoids</i>	303
Application of new technologies to pain therapeutics	303
<i>Application of nanobiotechnology to pain therapeutics</i>	304
<i>Technologies for the manufacture of analgesics</i>	305
Future trends and needs in pain management.....	305
Pain management in future healthcare systems	306
Systems biology approach to pain	306
Personalized pain management.....	307
Pharmacogenomics and pharmacogenetics of pain	308
Genetic mutations associated with reduced response to analgesics.....	309
Genetic mutations with loss of pain	309
Mechanism-specific management of pain	310
Preoperative testing to tailor postoperative analgesic requirements.....	310
Strategies for improving pain management.....	310
10. Companies Involved in Pain Therapeutics.....	312
Introduction	312
Profiles of companies.....	312
Collaborations.....	482
11. References.....	488

Tables

Table 1-1: Landmarks in the history of pain therapeutics.....	19
Table 1-2: Classification of pain	21
Table 1-3: Classification of neuropathic pain	23
Table 1-4: Classification of chronic cancer pain according to cause.....	24
Table 1-5: Percentage of patients with pain according to the type of cancer	25
Table 1-6: Key molecular elements of pain in the peripheral nervous system	47
Table 1-7: Key molecular elements of pain in the central nervous system	47
Table 2-1: IASP guidelines for the use of animals in pain studies	59
Table 2-2: Chronic pain as a manifestation of other diseases.....	60
Table 2-3: Recommendations for assessing patient satisfaction with pain management	65
Table 3-1: Classification of some currently used pain medications according to mechanism.....	72
Table 3-2: Drugs used for the treatment of pain	72
Table 3-3: Selective COX-2 inhibitors in clinical use for pain.....	74
Table 3-4: Antiepileptic drugs with analgesic effect	87
Table 3-5: Companies developing products to deter abuse of opioids	98
Table 4-1: Non-pharmacological approaches to management of pain	103
Table 4-2: Companies involved in neuromodulation therapy for pain	108
Table 4-3: Reasons for the inadequate management of acute pain.....	111
Table 4-4: Causes of chronic backache	126
Table 4-5: Management of chronic pelvic pain	129
Table 4-6: Management of pain in cancer	129
Table 4-7: Definitions of tolerance, physiological dependence, withdrawal and addiction.....	135
Table 4-8: A simplified classification of headache.....	136
Table 4-9: Various methods for the management of migraine.....	136
Table 4-10: Management of neuropathic pain based on mechanism and diagnosis	145
Table 4-11: Management of central neuropathic pain	148
Table 4-12: Current management of peripheral diabetic neuropathy	152
Table 4-13: Treatment strategies for postherpetic neuralgia.....	153

Table 4-14: Management of complex regional pain syndrome.....	155
Table 4-15: Methods of treating phantom limb pain	158
Table 4-16: Anti-itching therapies.....	164
Table 4-17: Suggested improvements in the management of pain	174
Table 5-1: A classification of drug delivery methods used in management of pain.....	176
Table 5-2: Selected marketed non-injection drug delivery systems for pain	180
Table 5-3: Spinal administration of drugs for pain.....	195
Table 5-4: Selected drug delivery systems for pain in clinical development	201
Table 6-1: Classification of drugs in development for pain.....	204
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics.....	209
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics.....	210
Table 6-4: NO-related therapies for pain.....	227
Table 6-5: Major opioids receptors and their ligands	230
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS	235
Table 6-7: Types of TRPV1 antagonists.....	236
Table 6-8: TRPV1 antagonists in clinical trials.....	237
Table 6-9: Experimental gene therapy approaches for relief of pain	244
Table 6-10: Selected preclinical approaches to pain therapy.....	251
Table 6-11: Selected preclinical drugs for neuropathic pain.....	253
Table 6-12: Selected clinical trials of miscellaneous drugs for pain	260
Table 6-13: Selected clinical trials of drugs for postsurgical pain.....	263
Table 6-14: COX-2 inhibitors in clinical development.....	265
Table 6-15: Disease modifying antirheumatic drugs in clinical trials	266
Table 6-16: Clinical trials of drugs for neuropathic pain	267
Table 6-17: Selected drugs in clinical development for migraine	276
Table 6-18: Therapeutic targets for treating visceral pain	279
Table 8-1: Market values for various painful conditions 2009-2019	288
Table 8-2: Changes in market shares of drugs for neuropathic pain 2009-2019	290
Table 8-3: Markets for pain according to therapies 2009-2019	291
Table 8-4: Distribution of value of pain therapeutics in major markets 2009-2019	294
Table 8-5: Distribution of value of opioids in major pain markets 2009-2019.....	294
Table 8-6: Distribution of value of NSAIDs in major pain markets 2009-2019.....	294
Table 8-7: Strategies for developing pain markets	296
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	308
Table 10-1: Product pipeline of Adolor Corporation	318
Table 10-2: Selected collaborations in the area of pain management	482

Figures

Figure 1-1: Afferent pain pathways.....	27
Figure 1-2: Evolution of the gate control theory.....	29
Figure 1-3: The body self-neurometric.....	30
Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	47
Figure 1-5: Prostaglandin biosynthesis pathway	51
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	61
Figure 2-2: Pain intensity scales	62
Figure 4-1: The WHO step ladder for pain	130
Figure 4-2: An algorithm for the acute management of migraine	137
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	144
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	157
Figure 4-5: Algorithm for management of patients with chronic pain and depression.....	161
Figure 5-1: Powder Injection Systems	187
Figure 6-1: Attributes of the ideal analgesic.....	205
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain	247
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	295
Figure 9-1: Impact of new technologies on pain therapeutics	304
Figure 9-2: A scheme of personalized management of pain	307